M&A Wave, Opdivo EU Nod & ASCO Data Lift Healthcare

Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, according to CNBC reporting. Gilead Sciences ($GILD), Merck & Co. ($MRK), and Eli Lilly ($LLY) are leading the takeover wave as acquirers. The robust deal activity reflects strategic consolidation as large pharmaceutical companies seek to bolster pipelines and offset upcoming patent expiries. Deal flow has accelerated compared to recent years as companies deploy capital to secure late-stage assets and commercial-stage products.

Bristol Myers Squibb ($BMY) received European Commission approval for Opdivo (nivolumab) in combination with AVD chemotherapy as the first immunotherapy-based frontline regimen for adults and adolescents with previously untreated Stage III or IV classical Hodgkin lymphoma in the EU. This decision expands Opdivo's reach into earlier-stage treatment of a cancer that is especially common in adolescents and young adults, potentially broadening Bristol Myers Squibb's hematology-oncology footprint. The approval follows clinical data supporting the regimen's efficacy in first-line treatment. Separately, analysts noted that $BMY offers a 4.43% dividend yield with strong profitability, though a high payout ratio and declining earnings pose sustainability risks.

At the ASCO26 conference, Merck & Co. ($MRK) showcased solid tumor data readouts that outline the company's oncology prowess, with Keytruda continuing to demonstrate strong performance in solid tumors. Other $MRK pipeline assets signal designs to address Keytruda's upcoming exclusivity loss. Moderna ($MRNA) shares gained 5.1% after the company, along with partner $MRK, presented positive long-term data for its personalized mRNA-based cancer vaccine. The positive momentum extended earlier gains as the data underscored progress in Moderna's efforts to prove its platform capabilities extend beyond COVID-19 vaccines. The ASCO presentations provided investors with updated efficacy and safety profiles across multiple oncology candidates.

Insulet Corporation ($PODD) began rolling out FDA-cleared algorithm enhancements to its Omnipod 5 Automated Insulin Delivery System in the U.S. in early June 2026, adding a 100 mg/dL target option and new compatibility with Abbott Laboratories' ($ABT) Libre 3 Plus sensor via over-the-air updates and newly shipped Pods. This combination of tighter glucose personalization, improved automated mode performance, and broader sensor choice strengthens Omnipod 5's appeal for both patients and clinicians. Intuitive Surgical ($ISRG) shares have fallen 25.5% year to date, trading at $418.82, prompting valuation questions despite the company's promotion of Taylor Patton to Chief Commercial and Marketing Officer to focus on global scaling and AI-driven surgery initiatives. The global cardiac monitoring and cardiac rhythm management devices market is projected to reach $37.88 billion by 2031, up from $27.90 billion in 2026, with a CAGR of 6.3%, driven by rising awareness and early cardiovascular disease detection, with $ABT positioned as a key player.

UnitedHealth Group ($UNH) shares jumped 5.4% after Bank of America upgraded the company to Buy from Neutral and the company announced an increased quarterly dividend. The dividend hike is drawing attention as investors seek stability amid inflation and geopolitical uncertainty. WeightWatchers ($WW) shares gained after the company announced its Weight Watchers Med+ program is now accessible through Eli Lilly's ($LLY) digital healthcare platform, LillyDirect, intensifying competition in the digital weight management and GLP-1 medication space. Amgen ($AMGN) executives used a Jefferies investor conference appearance to emphasize the company's first-quarter growth, its late-stage pipeline, and its preparations for potential launches, including the obesity candidate MariTide.

Gilead Sciences ($GILD) applauded the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication, marking an important step toward expanding access to lenacapavir for communities most affected by HIV. Thermo Fisher Scientific ($TMO) showcased its new Thermo Scientific Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at the ASMS Conference in late May 2026, highlighting faster, more sensitive multiomics and complex drug development analysis alongside AI-enabled software and its Olink proteomics platform. By pairing these Orbitrap systems with recent AI-focused software acquisitions and expanded bioanalytical labs in Sweden, $TMO is deepening its role across the entire drug discovery and development workflow.